Literature DB >> 8772467

A role for CFTR in human autosomal dominant polycystic kidney disease.

K Hanaoka1, O Devuyst, E M Schwiebert, P D Wilson, W B Guggino.   

Abstract

Human autosomal dominant polycystic kidney disease (ADPKD) is the most common lethal dominant hereditary disorder characterized by enormous renal enlargement and the development of multiple cysts originating from nephrons. We investigated the pathogenesis of cyst formation in ADPKD by using patch-clamp and immunocytochemical techniques. Adenosine 3',5'-cyclic monophosphate-activated Cl- currents are present in primary cultures of ADPKD cells and have characteristics such as a linear current-voltage relation, insensitivity to 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid, sensitivity to glibenclamide and diphenylamine carboxylic acid, and an anion selectivity sequence of Br- > Cl- > I- > glutamate, all of which are identical to cystic fibrosis transmembrane conductance regulator (CFTR). With the use of CFTR antibodies raised against the regulatory and first nucleotide-binding domains, CFTR was detected in primary cultures of ADPKD cells. Similar results were obtained in vivo in cyst-lining epithelial cells in ADPKD kidneys, where staining was seen associated with the apical membrane regions. These data indicate that the CFTR Cl- channel exists in apical membranes of ADPKD cells and may play an important role in cyst formation or enlargement.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8772467     DOI: 10.1152/ajpcell.1996.270.1.C389

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  36 in total

Review 1.  Polycystic kidney disease: In danger of being X-rated?

Authors:  J J Grantham; J P Calvet
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  P2 receptors in renal pathophysiology.

Authors:  Clare M Turner; James I Elliott; Frederick W K Tam
Journal:  Purinergic Signal       Date:  2009-06-09       Impact factor: 3.765

Review 3.  Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.

Authors:  Takamitsu Saigusa; P Darwin Bell
Journal:  Physiology (Bethesda)       Date:  2015-05

4.  Polycystin-1, 2, and STIM1 interact with IP(3)R to modulate ER Ca release through the PI3K/Akt pathway.

Authors:  Netty G Santoso; Liudmila Cebotaru; William B Guggino
Journal:  Cell Physiol Biochem       Date:  2011-06-17

Review 5.  Polycystic kidney disease: huge kidneys, huge problems, huge progress.

Authors:  J J Grantham
Journal:  Trans Am Clin Climatol Assoc       Date:  1997

6.  Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.

Authors:  Liudmila Cebotaru; Qiangni Liu; Murali K Yanda; Clement Boinot; Patricia Outeda; David L Huso; Terry Watnick; William B Guggino; Valeriu Cebotaru
Journal:  Kidney Int       Date:  2016-03-25       Impact factor: 10.612

Review 7.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

8.  Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells.

Authors:  S R Brill; K E Ross; C J Davidow; M Ye; J J Grantham; M J Caplan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

9.  Tight junction composition is altered in the epithelium of polycystic kidneys.

Authors:  A S L Yu; S A Kanzawa; A Usorov; I S Lantinga-van Leeuwen; D J M Peters
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

10.  Bardet-Biedl syndrome proteins 1 and 3 regulate the ciliary trafficking of polycystic kidney disease 1 protein.

Authors:  Xuefeng Su; Kaitlin Driscoll; Gang Yao; Anas Raed; Maoqing Wu; Philip L Beales; Jing Zhou
Journal:  Hum Mol Genet       Date:  2014-06-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.